Article info
Correspondence
Comment on: ‘Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al
- Correspondence to Professor David Isenberg, Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK; d.isenberg{at}ucl.ac.uk
Citation
Comment on: ‘Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al
Publication history
- Received September 20, 2018
- Accepted September 22, 2018
- First published October 29, 2018.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.